Fortrea’s $45M Phase I Grab Is Your Vendor Continuity Problem Now
Fortrea's $45M acquisition of Worldwide Clinical Trials' early-phase division reshapes Phase I site networks and vendor contracts for sponsors...
CRO Consolidation
Fortrea’s $45M Early Phase Deal Sets a 90-Day Test for Sponsors With Active Studies
Fortrea's $45M buy of Worldwide Clinical Trials' Early Phase Services unit means active sponsors face contract novation, lab method...
When Your CRO Gets Acquired, Your Site Activation Timeline Pays the Price
Curavit's acquisition of Lindus Health CRO assets combines 1,000+ global sites with DCT infrastructure—but site teams absorb the operational...
When Your CRO Merges Mid-Study, the Site Pays the Price
Caidya and Simbec-Orion's merger creates a 6-month operational danger zone for sites running active studies. Here's what sponsor clinops...
When Two CROs Become One, Sites Pay the Integration Tax
Caidya and Simbec-Orion's June 2026 merger creates real site-level friction: dual CTMS logins, monitoring model gaps, and budget renegotiations...
When the Vendor Consolidates, Sites Feel It First
WCG's acquisition of The Contract Network promises faster trial startup—but site coordinators know vendor mergers rarely simplify the contracts...